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Patent Foramen Ovale Science
Keeping the Horse in Front of the Cart*
Deeb N. Salem, MD,yz David E. Thaler, MDx
Boston, Massachusetts
Compared with a prevalence of 25% in the general population,
the higher prevalence of patent foramen ovale (PFO) in
cryptogenic stroke (CS) patients has led to the intuitive
conclusion that PFO is a risk factor for CS (1). However,
distinguishing truly culpable PFOs from the innocent
bystanders has been difﬁcult. Some have advocated closure for
just about any PFO (2), an approach which subjects people
(many are not yet “patients”with anyPFO-related neurological
or other clinical syndrome) to procedural and device-related
risks. This clearly puts the cart before the horse. PFO closure
for secondary stroke prevention continues to be controversial
even after 3 published randomized clinical trials (3–5). Primary
stroke prevention with PFO closure is entirely unstudied.
See page 35
For some, PFO interventions have become an acceptable
part of the routine armamentarium for secondary stroke
prevention well before the resolution of many issues that
make this a confusing and complicated subject. Patient
selection, nonstandard diagnostic testing and CS deﬁnition,
and devices with different safety proﬁles bedevil doctors
looking after these patients. The observational, nonran-
domized data from the last decade were biased in favor of
showing a beneﬁt from device closure. Device studies more
often included patients without stroke (and so likely lower
“recurrence” rates than a CS population), failed to use vali-
dated screening tools for outcome ascertainment, failed to
require neurologist involvement, and did not require neuro-
imaging (6). Compared to the observational data, the recently
completed PFO closure trials showed higher recurrent stroke
rates in the device groups (probably due to better outcome
ascertainment) and lower recurrent stroke rates in the medi-
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is that the natural history of PFO-related stroke is relatively
benign compared with other stroke categories. If PFO closure
works, it will only be in carefully selected patients with a high
risk of PFO-related recurrence in whom a device with a low
risk of device-related complications is safely deployed.
Therefore, even if the consensus is that PFO closure is helpful,
there will still be some PFOs that are better left alone.
Of course, those of us interested in winning the cerebro-
vascular war would like to prevent the ﬁrst stroke rather than
ﬁght only after the initial battle is already lost. Device closure
was widely applied in secondary prevention efforts before the
science was available to conﬁrm that the right patients were
being treated and that they beneﬁted in a statistically mean-
ingful way (6). For primary stroke prevention, PFO closure is
not yet widely offered, so we have the opportunity to keep the
horse of science ﬁrmly in front of the cart of practice.
Otherwise, PFO closure may be considered, and used, in the
general asymptomatic population, where 25% of people may
be unscientiﬁcally, and unnecessarily, turned into patients.
In this issue of the Journal, Di Tullio et al. (7) present
data from the Northern Manhattan Study (NOMAS) that
attempt to ﬁll in gaps in knowledge about harm from PFO
in the general population. It is just this sort of study that
will inform physicians’ and patients’ decisions about what,
if anything, to do about an incidentally discovered PFO.
Their paper uses prospectively collected data from an
ongoing population-based study. They recruited 1100 people
over 39 years old, stroke free, and living in northern
Manhattan between 1993 and 1999. All subjects underwent
baseline transthoracic echocardiography with saline contrast
injection. PFO prevalence was 14.9%. All participants
underwent annual protocol-required neurological follow-up
and were assessed for cerebrovascular symptoms. Follow-up
was impressive, with data available for 98% of subjects at
10 years. A subpopulation (n¼ 360) had magnetic resonance
imaging (MRI) scans to assess for radiologically apparent
but clinically silent infarcts. Subjects in the substudy were
55 years old and older when it was conducted (2003 to
2008). After a mean of 11 years, the incidence of ﬁrst ever
strokewas 9.2% in the PFOgroup and 10.3% in those without
PFO. The adjusted hazard ratio for PFO was 1.10 (95%
conﬁdence interval [CI]: 0.64 to 1.91). Similarly, the hazard
ratio of PFO for clinically silent but radiologically apparent
stroke was not signiﬁcant at 1.15 (95% CI: 0.50 to 2.62).
How can PFO be a risk factor for stroke (1) but not show
up in this population study?
First, subjects had PFO status determined by a diagnostic
test (transthoracic echocardiography) which has a sensitivity
of approximately 50%. The very low prevalence of PFO in
their population (14.9%) belies this fact. Some in the non-
PFO group, therefore, must have been harboring one. The
argument that only the “less signiﬁcant” PFOs were missed
follows the logic that large shunts are more dangerous. This
is intuitive but unproven and even contrary to some data that
suggest recurrence is predicted by smaller shunts (8,9).
JACC Vol. 62, No. 1, 2013 Salem and Thaler
July 2, 2013:42–3 Patent Foramen Oval
43Second, although PFO-associated strokes do occur in
older patients (10), the PFO proportion of all strokes falls
considerably as competing stroke mechanisms (e.g., atrial
ﬁbrillation, atherosclerosis, lacunar disease) become more
prevalent with age (11). The transition point from a young
stroke patient to an old one is unclear but is probably in the
mid-40s (12). The population in this study (mean age ¼
68 years old) was not young. Conventional vascular diseases
likely “drowned out” the PFO-associated risk that might
have been detectable in a study of younger subjects. The
unusually high prevalence of hypertension in this cohort
(>60%) increases this concern. As additional support for the
contamination of non–PFO-related stroke mechanisms,
hypertension was signiﬁcantly, and not surprisingly, associ-
ated with silent stroke in the MRI substudy. It has never
been suggested that hypertension and PFO synergistically
increase stroke risk, so the more conventional hypertension-
related pathologies must have been involved.
For years, the NOMAS team has produced very high
quality studies. Except for the issues described above, we have
no concerns with the protocol or study conduct. The neuro-
imaging and follow-up were exemplary. Studies of this type
are needed. Unfortunately these data do not settle this issue. If
a population at risk from their PFOs is going to be identiﬁed
before their ﬁrst stroke, it needs to be done in people who are
in their 20s and 30s (and perhaps 40s), with PFO status
deﬁned by transesophageal echocardiography or transcranial
Doppler and perhaps also described in detail beyond present/
absent, and with or without atrial septal aneurysm. A focus on
asymptomatic subpopulations that may be at higher risk of
a ﬁrst-ever stroke, for example, those with migraine with aura
(13), obstructive sleep apnea (14), and silent infarcts (15), is
likely to increase the success of the next population-based
study.
Reprint requests and correspondence: Dr. Deeb N. Salem, Tufts
Medical Center, Department of Medicine, Box 079, 800
Washington Street, Boston, Massachusetts 02111. E-mail:
DSalem@tuftsmedicalcenter.org.REFERENCES
1. Kent DM, Thaler DE. Is patent foramen ovale a modiﬁable risk factor
for stroke recurrence? Stroke 2010;41 Suppl 1:S26–30.
2. Meier B. Closure of patent foramen ovale: technique, pitfalls,
complications, and follow-up. Heart 2005;91:444–8.
3. Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for
cryptogenic stroke with patent foramen ovale. N Engl J Med 2012;366:
991–9.
4. Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale
versus medical therapy after cryptogenic stroke. N Engl J Med 2013;
368:1092–100.
5. Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent
foramen ovale in cryptogenic embolism. N Engl J Med 2013;368:
1083–91.
6. Kitsios GD, Dahabreh IJ, Abu Dabrh AM, et al. Patent foramen ovale
closure and medical treatments for secondary stroke prevention. Stroke
2012;43:422–31.
7. DiTullio MR, Zhezhen Jin, Russo C, et al. Patent foramen ovale,
subclinical cerebrovascular disease, and ischemic stroke in a population-
based cohort. J Am Coll Cardiol 2013;62:35–41.
8. Homma S, Sacco RL, DiTullio MR, et al. Effect of medical treatment
in stroke patients with patent foramen ovale: patent foramen ovale in
Cryptogenic Stroke Study. Circulation 2002;105:2625–31.
9. Thaler DE, Ruthazer R, Di Angelantonio E, et al. PFO and recurrent
stroke: predictors differ in patients with “probable pathogenic” versus
other PFOs (absr). Stroke 2013;44:A198.
10. Handke M, Harloff A, Olschewski M, et al. Patent foramen ovale
and cryptogenic stroke in older patients. N Engl J Med 2007;357:
2262–8.
11. Go AS, Mozaffarian D, Roger VL, et al. American Heart
Association Statistics Committee and Stroke Statistics Subcom-
mittee. Heart disease and stroke statistics. Circulation 2013;127:
e6–245.
12. Putaala J, Metso AJ, Metso TM, et al. Analysis of 1008 consecutive
patients aged 15 to 49 with ﬁrst-ever ischemic stroke. Stroke 2009;40:
1195–203.
13. Sacco S, Ricci S, Carolei A. Migraine and vascular diseases: a review of
the evidence and potential implications for management. Cephalalgia
2012;32:785–95.
14. Thomas JJ, Ren J. Obstructive sleep apnea and cardiovascular
complications: perception versus knowledge. Clin Exp Pharmacol
Physiol 2012 Oct 19 [E-pub ahead of print]; http://dx.doi.org/1
0.1111/1440-1681.12024.
15. Gioia LC, Tollard É, Dubuc V, et al. Silent ischemic lesions in young
adults with ﬁrst stroke are associated with recurrent stroke. Neurology
2012;79:1208–14.Key Words: atrium - cerebrovascular disorders - echocardiography -
epidemiology - stroke.
